Advertisement


Lee S. Schwartzberg, MD, on HR+ Breast Cancer: Treatment Trial Results

2017 San Antonio Breast Cancer Symposium

Advertisement

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase II study findings evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer (Abstract GS4-07).



Related Videos

Breast Cancer

Eun-Sil Shelley Hwang, MD, on DCIS: Results of the CALGB 40903 Trial

Eun-Sil Shelley Hwang, MD, of Duke University Medical Center, discusses study findings on primary endocrine therapy for estrogen receptor–positive ductal carcinoma in situ (Abstrac...

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: the PADMA Trial

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses a study evaluating palbociclib plus endocrine treatment vs a chemotherapy-based treatment strategy in patients with ho...

Breast Cancer

Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a no...

Issues in Oncology

SABCS 40th Anniversary Award Lecture: Richard Pazdur, MD, on Cancer Drug Development

Richard Pazdur, MD, of the U.S. Food & Drug Administration’s Oncology Center of Excellence, discusses the rapid changes in evaluating and approving new and effective agents, in...

Breast Cancer

Eric S. Winer, MD, on Metastatic Breast Cancer: Debate on a Research Tool

Eric S. Winer, MD, of the Dana-Farber Cancer Institute, addresses the much-discussed controversy over whether all women diagnosed with metastatic breast cancer should undergo next-...

Advertisement

Advertisement



;
Advertisement